Navigation Links
Potential vaccine developed for deadly leishmaniasis disease

Development of a fundamentally new "candidate," or potential, vaccine for visceral leishmaniasis, a parasitic disease that kills about 60,000 people annually, is reported in the current issue of ACS Chemical Biology. Spread by the bite of infected female sand flies, visceral leishmaniasis infects about 500,000 people annually, with the majority of cases occurring in India, Bangladesh, Nepal, Sudan and Brazil.

Despite a major research thrust by the World Health Organization (WHO), no effective vaccine exists for the visceral, or internal, form of leishmaniasis. A milder form of leishmaniasis, which infects the skin, was reported among American military personnel during Operation Desert Storm and other conflicts in the region.

Peter H. Seeberger, Ph.D., of the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich headed the research group. It also included researchers from the Swiss Tropical Institute in Basel and Pevion Inc., a biotech company focusing on virosomal delivery systems. The group reported their findings in ACS Chemical Biology, one of 34 peer-reviewed journals published by the American Chemical Society, the world’s largest scientific society.

Several leishmaniasis candidate vaccines are in various stages of development. Seeberger’s group, however, reported development of a unique two-part preparation. It is among a new genre of carbohydrate-based vaccines stirring excitement in medical circles. Carbohydrates are chemical compounds that include sugar and are made from units linked together like beads on a chain.

"This is the first and only carbohydrate vaccine candidate against this disease," Seeberger stated. "This candidate vaccine brings something new to the table and may be of use not only in humans but also for pet vaccines. Dogs get leishmaniasis, particularly in Southern Europe and a vaccine is urgently needed there, as well."

Carbohydrate vaccines alre
'"/>

Source:American Chemical Society


Page: 1 2 3

Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. Potential treatments for neurofibromatosis
4. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
5. Potential Drug Target For Treating Cocaine Abuse Found
6. Potential heart benefit found in stem cells
7. Research advances quest for HIV-1 vaccine
8. A much-needed shot in the arm for HIV vaccine development
9. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
10. Gene vaccine for Alzheimers disease shows promising results
11. Influenza vaccine uses insect cells to speed development
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potential vaccine developed for deadly leishmaniasis disease

(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... researchers has identified 11 new genes that offer ... in Alzheimer,s disease. The highly collaborative effort involved ... genetic analysis yet conducted in Alzheimer,s researchto discover ... disease, the most common form of the disorder. ...
... Cell culture systems for specific neural cell types ... function. Purifying and Culturing Neural Cells: A ... cell populations from rodent tissues and culturing them ... The contributors describe in detail how to dissect ...
... penetrating icy blue glare of car headlights and could be fundamental ... the heart of diodes. Not the kind you might find in ... gallium nitride or InGaN. This alloy forms the light emitting region ... diodes (LDs) in the blue-UV range. Research into making ...
Cached Biology News:NIH-supported study identifies 11 new Alzheimer's disease risk genes 2NIH-supported study identifies 11 new Alzheimer's disease risk genes 3ASU, Georgia Tech create breakthrough for solar cell efficiency 2
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... 2011 BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products marketed as XIAFLEX ® in the U.S. ... announced the appointment of  George Gould, Esq., to its ... an attorney, is Principal of George M. Gould, LLC, ...
... 2011  Janssen Biotech, Inc., one of the Janssen Pharmaceutical ... ), announced today that it has executed an agreement ... jointly develop and market the anti-cancer compound, PCI-32765.  A ... are ongoing across a panel of B-cell malignancy disorders, ...
... December 8, 2011 The Joint Management ... (ENPI CBC MED program) has informed Prof Nava ... they will award a contract of up to 2 ... and directed by Hadassah College, will be implemented in ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 2Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 3The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem 2
...
... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
...
Biology Products: